<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="273">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01756729</url>
  </required_header>
  <id_info>
    <org_study_id>EF-19</org_study_id>
    <nct_id>NCT01756729</nct_id>
  </id_info>
  <brief_title>Post-approval Study of NovoTTF-100A in Recurrent GBM Patients</brief_title>
  <official_title>A Prospective, Non-randomized, Concurrent Control, Open Label, Post-approval Study of NovoTTF-100A in Recurrent GBM Patient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovoCure Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NovoCure Ltd.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-randomized, concurrent control study, designed to confirm that the efficacy of
      the NovoTTF-100A System in patients with recurrent GBM treated in a real life settings
      following approval is comparable to that of BSC chemotherapy patients. The device is a
      portable, battery operated device that  was approved for the treatment of adult patients (22
      years of age or older) with histologically-confirmed glioblastoma multiforme (GBM),
      following histologically- or radiologically-confirmed recurrence in the supra-tentorial
      region of the brain after receiving chemotherapy. The device is intended to be used as a
      monotherapy, and is intended as an alternative to standard medical therapy for GBM after
      surgical and radiation options have been exhausted.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PAST CLINICAL EXPERIENCE:

      The effect of the electric fields generated by the NovoTTF-100A device (TTFields, TTF) has
      been tested in a large prospective, randomized trial, in 237 recurrent GBM patients. The
      outcome of subjects treated with the NovoTTF-100A device was compared to those treated with
      an effective best standard of care chemotherapy (including bevacizumab). NovoTTF-100A
      subjects had comparable overall survival to subjects receiving the best available
      chemotherapy in the US today. Similar results showing comparability of NovoTTF-100A to BSC
      chemotherapy were seen in all secondary endpoints.

      Recurrent GBM patients treated with the NovoTTF-100A device in this trial experienced fewer
      side effects in general, significantly fewer treatment related side effects, and
      significantly lower gastrointestinal, hematological and infectious adverse events compared
      to controls. The only device-related adverse events seen were a mild to moderate skin
      irritation beneath the device electrodes. Finally, quality of life measures were better in
      NovoTTF-100A subjects as a group when compared to subjects receiving effective best standard
      of care chemotherapy.

      DESCRIPTION OF THE TRIAL:

      Patients with GBM whose disease has first recurred despite standard treatment (Surgery,
      radiation therapy, Temozolomide treatment) and meet all of the requirements for
      participation in the study will be recruited to one of two groups based on patient
      preference alone:

        1. Treatment with the NovoTTF-100A device, or

        2. Treatment with the best standard of care practiced at each of the participating
           centers.

      If recruited to the best standard of care group, patients will receive a chemotherapeutic
      agent chosen based on their prior treatments and the standard of care practiced at each
      treating center.

      If recruited to the NovoTTF-100A group, the patients will be treated continuously until
      tumor progression. NovoTTF-100A treatment will consist of wearing four electrically
      insulated electrodes on the head. Electrode placement will require shaving of the scalp
      before treatment. Patients will continue treatment at home where they can maintain their
      regular daily routine.

      During the trial, regardless of whether assigned to the NovoTTF-100A treatment group or the
      best standard of care group, patients will need to return once every month the hospital
      outpatient clinics where they will be examined by a physician. These routine visits will
      continue for as long as the patient's disease is not progressing.

      During the visits to the clinic patients will be examined physically and neurologically, as
      well as fill in neuro-cognitive questionnaires. Adverse events data will be collected from
      all patients.. After this follow up plan, patients will be contacted once per month by
      telephone to answer basic questions about their health status.

      SCIENTIFIC BACKGROUND:

      TTFields are alternating electric fields of low intensity. This means that they change their
      direction repetitively many times a second. Since they change direction very rapidly (200
      thousand times a second), they do not cause muscles to twitch, nor do they have any effects
      on other electrically activated tissues in the body (brain, nerves and heart). Since the
      intensities of TTFields in the body are very low, they do not cause heating.

      The breakthrough finding made by NovoCure was that finely tuned alternating fields of very
      low intensity, now termed TTFields (Tumor Treating Fields), cause a significant slowing in
      the growth of cancer cells. Due to the unique geometric shape of cancer cells when they are
      multiplying, TTFields cause the building blocks of these cells to move and pile up in such a
      way that the cells physically explode. In addition, cancer cells also contain miniature
      building blocks which act as tiny motors in moving essential parts of the cells from place
      to place. TTFields cause these tiny motors to fall apart since they have a special type of
      electric charge.

      As a result of these two effects, cancer tumor growth is slowed and can even reverse after
      continuous exposure to TTFields.

      Other cells in the body (normal healthy tissues) are affected much less than cancer cells
      since they multiply at a much slower rate if at all. In addition TTFields can be directed to
      a certain part of the body, leaving sensitive areas out of their reach.

      In conclusion, TTField hold the promise of serving as a brand new cancer treatment with very
      few side effects and promising affectivity in slowing or reversing this disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years from initiation of accrual</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in neuro-cognitive function from baseline based on MMSE</measure>
    <time_frame>5 years from initiation of accrual</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic profiling of tumors and correlation with response to NovoTTF-100A treatment</measure>
    <time_frame>5 years from initiation of accrual</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events severity and frequency</measure>
    <time_frame>5 years from initiation of accrual</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">486</enrollment>
  <condition>Recurrent Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Best Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients recruited to the BSC group will be treated according to the BSC practiced at each center.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NovoTTF-100A (monotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated continuously with the NovoTTF-100A device. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NovoTTF-100A</intervention_name>
    <description>Multiple four-week courses of continuous NovoTTF-100A treatment.</description>
    <arm_group_label>Best Standard of Care</arm_group_label>
    <arm_group_label>NovoTTF-100A (monotherapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 22 years of age or older

          2. Histological diagnosis of GBM (WHO grade IV)

          3. Tumor located in the supra-tentorial region of the brain

          4. Received maximal, safe, surgical resection

          5. Received maximal radiation therapy

          6. Received concomitant Temozolomide

          7. Received maintenance Temozolomide

          8. First recurrence (based on radiological or histological evidence of recurrence)

          9. Karnofsky performance score 70 or above

         10. MMSE score 25 or above

         11. Adequate amount and quality of tumor tissue from first surgical resection available
             for genetic profiling

         12. Women of childbearing age must be on effective contraception

         13. Signed informed consent

         14. Stable steroid dose in past 4 weeks

        Exclusion Criteria:

          1. Implanted electronic medical device in the brain:

               1. Deep brain stimulator

               2. Vagus nerve stimulator

               3. Programmable shunt

          2. Skull defect without replacement

          3. Unable to comply with treatment with the NovoTTF-100A device

          4. Pregnant

          5. Prior antiangiogenic therapy (e.g., Bevacizumab/Avastin)

          6. Second or subsequent recurrence

          7. Any prior cytotoxic chemotherapy except Temozolomide

          8. Actively participating in another therapeutic clinical trial

          9. Radiological suspicion of pseudoprogression or radionecrosis

         10. Radiation therapy or surgery in the past 4 weeks

         11. Unable to comply with the study follow-up schedule

         12. Any serious co-morbidity which is expected to affect survival more adversely than GBM
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert Engelhard, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ghazala Kabani</last_name>
    <email>patientinfo@novocure.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel Nguyen</last_name>
      <phone>858-822-0201</phone>
      <email>anguyen85@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Santosh Kesari, M.D., PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herbert Engelhard, MD, PhD</last_name>
      <phone>312-282-5821</phone>
      <email>hengel@uic.edu</email>
    </contact>
    <investigator>
      <last_name>Herbert Engelhard, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky, Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tonya Gardner</last_name>
      <phone>859-323-0532</phone>
      <email>tonya.gardner@uky.edu</email>
    </contact>
    <investigator>
      <last_name>John Villano, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine, Division of Oncology</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abigail S Gwinn</last_name>
      <phone>314-747-4678</phone>
      <email>AGWINN@DOM.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>David Tran, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Long Island Brain Tumor Center</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Prabhu</last_name>
      <email>kprabhu@nspc.com</email>
    </contact>
    <investigator>
      <last_name>Jai Grewal, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Duic, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, Schatzberger R, Palti Y. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004 May 1;64(9):3288-95.</citation>
    <PMID>15126372</PMID>
  </reference>
  <reference>
    <citation>Kirson ED, Dbaly V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Gurvich Z, Schneiderman R, Wasserman Y, Salzberg M, Ryffel B, Goldsher D, Dekel E, Palti Y. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10152-7. Epub 2007 Jun 5.</citation>
    <PMID>17551011</PMID>
  </reference>
  <reference>
    <citation>Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbal√Ω V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012 Sep;48(14):2192-202. doi: 10.1016/j.ejca.2012.04.011. Epub 2012 May 18.</citation>
    <PMID>22608262</PMID>
  </reference>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 12, 2013</lastchanged_date>
  <firstreceived_date>December 20, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brain tumor</keyword>
  <keyword>Treatment</keyword>
  <keyword>Minimal toxicity</keyword>
  <keyword>GBM</keyword>
  <keyword>Glioblastoma</keyword>
  <keyword>Recurrent</keyword>
  <keyword>TTFields</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
